Uncovering the mystery behind white squirrel sightings in central Ohio
COLUMBUS, Ohio (WCMH) — White squirrels are once again catching the eyes and imaginations of people in central Ohio.
A recent traveler to Columbus sent NBC4 pictures of his encounter with the striking rodent in the Victorian Village area.
'I was visiting relatives at Harrison on 5th by Senior Star for about ten days and took our dog on several long walks a day through the beautiful neighborhood,' wrote Slawomir Siejka in an email to NBC4. 'It's a great area for walking, but the highlight was definitely seeing this beautiful white squirrel at about Fifth and Michigan. I had never seen one and kind of couldn't believe my eyes at first.'
List: 2025 last day of school dates around Columbus and central Ohio
According to the Ohio Division of Wildlife, most white squirrels in these sightings are, in reality, eastern gray squirrels. Ohio's other species of squirrels, including the American red squirrel, fox squirrel, and the southern flying squirrel, can also be white or even black.
Wildlife Management Supervisor Gary Comer explained that when it comes to 'squirrels that exhibit unique colors,' there are three genetic possibilities.
The first is albinism, which results in the absence of pigment in the skin, fur, and eyes, leading to a white appearance with pink or blue eyes. Estimates suggest a female gray squirrel has a 1 in 100,000 chance of giving birth to an albino offspring. The second is leucism, which causes a partial loss of pigment, resulting in a paler or whiter coat, but the eyes are usually dark. The third is melanism, where an increased amount of black or nearly black pigmentation in an organism results in a darker appearance.
Many white squirrel images NBC4 has received over the years, like Siejka's, were taken around Victorian Village and Goodale Park. Comer revealed that there can be established 'colonies' of white squirrels, either albino or leucistic, where these variations are more common. The traits of albinism or leucism are often found in pockets and many individuals can share a common ancestry.
'To some people, white squirrels are also known as mythological creatures that symbolize the coming of change and the need to prepare for it,' said Comer. 'Or, they could be a symbol of good luck, mainly because you don't see them very often.'
Ohioans get green light to collect signatures to get property tax issue on ballot
These legends or folklore might seem prophetic to Siejka.
'I've just recently moved to the U.S. from Poland and sent the photos to my extended family in Gdynia — also very amazed!' Siejka told NBC4.
One other detail Comer shared was that white squirrels can be more vulnerable to predators due to their increased visibility. Exhibiting a stark contrast with their environment and potential vision deficiencies puts them at risk.
However uncommon white squirrels might be in the Buckeye State, finding out what squirrel is most prevalent might be even more surprising.
'The most common squirrel in Ohio, believe it or not, is the flying squirrel,' Comer said. 'Most people are completely unaware of flying squirrels as they are nocturnal and almost all of their activity is at night.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
10 hours ago
- New York Post
Menopause drug might prevent breast cancer and treat hot flashes, research finds
A drug intended to treat menopause symptoms could double as breast cancer prevention. New research from Northwestern University in Illinois found that Duavee, a Pfizer-made drug, 'significantly reduced' breast tissue cell growth, which is a major indicator of cancer progression. Advertisement A phase 2 clinical trial included 141 post-menopausal women who had been diagnosed with ductal carcinoma in situ (DCIS), also known as stage 0 breast cancer, according to a press release from Northwestern. This non-invasive breast cancer affects more than 60,000 American women each year, often leading to an outcome of invasive breast cancer. The women were separated into two groups — one received Duavee and the other took a placebo for a month before undergoing breast surgery. Duavee is a conjugated estrogen/bazedoxifene (CE/BZA) drug, which combines estrogen with another medication that minimizes the potential harmful side effects of the hormone. Advertisement 'The key takeaway from the study is that CE/BZA slows the growth (proliferation) of cells in milk ducts of DCIS that expressed the estrogen receptor significantly more than placebo,' Dr. Swati Kulkarni, lead investigator and professor of breast surgery at Northwestern University Feinberg School of Medicine, told Fox News Digital. 5 New research from Northwestern University found that the drug Duavee 'significantly reduced' breast tissue cell growth, a major indicator of cancer progression. Marko Geber – Another major finding is that the quality of life did not differ significantly between the two groups, but patients who took the CE/BZA reported fewer hot flashes during the study, she noted. 'This would be expected, as the drug is FDA-approved to treat hot flashes.' Advertisement Kulkarni presented the study last week at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. 5 The women in the study were separated into two groups — one received Duavee and the other took a placebo for a month before undergoing breast surgery. Gorodenkoff – 5 Those who took the drug reported fewer hot flashes during the study. fizkes – The findings are preliminary and have not yet been published in a medical journal. Advertisement 'What excites me most is that a medication designed to help women feel better during menopause may also reduce their risk of invasive breast cancer,' said the doctor, who is also a Northwestern Medicine breast surgeon. Women who face a higher risk of breast cancer — including those who have experienced 'high-risk lesions' — and who also have menopausal symptoms are most likely to benefit from the drug, according to Kulkarni. 'These women are typically advised against standard hormone therapies, leaving them with few menopausal treatment options,' the release stated. Study limitations The researchers said they are 'encouraged' by these early results, but more research is required before the medication can be considered for approval as a breast cancer prevention mechanism. 'Our findings suggest that CE/BZA may prevent breast cancer, but larger studies with several years of follow-up are needed before we would know this for sure,' Kulkarni told Fox News Digital. Dr. Sheheryar Kabraji, chief of breast medicine at the Roswell Park Comprehensive Cancer Center in Buffalo, New York, was not involved in the study but commented on the findings. 5 'What excites me most is that a medication designed to help women feel better during menopause may also reduce their risk of invasive breast cancer,' Dr. Swati Kulkarni said. sarayutsridee – Advertisement 'While intriguing, this study is highly preliminary, and more research will be needed before we can conclude that conjugated estrogen/bazedoxifene (CD/BZA), a form of the hormone estrogen commonly prescribed to address symptoms of menopause, prevents invasive breast cancer or is effective at reducing cancer risk,' he told Fox News Digital. Kabraji also noted that the study focused on reducing levels of one specific protein, 'which does not always predict reduced recurrence of breast cancer.' 'This study did not directly show that CE/BZA treatment reduces the risk of DCIS recurrence or development of invasive cancer,' he noted. 5 According to Kulkarni,'larger studies with several years of follow-up are needed' to confirm that the drug prevents breast cancer. Science RF – Advertisement 'Importantly, however, patients who received this therapy experienced no worsening of quality of life, and saw improvement in vasomotor symptoms, such as hot flashes. If found to be effective in preventing breast cancer, CE/BZA is likely to have fewer side effects than current medications used for breast cancer prevention.' Lead researcher Kulkarni emphasized that this medication is not for the treatment of invasive breast cancer or DCIS. 'Right now, we can say that women who are concerned about their risk of developing breast cancer can consider this medication to treat their menopausal symptoms,' she added.
Axios
15 hours ago
- Axios
The great poaching: America's brain drain begins
The Trump administration's spending cuts and restrictions on foreign students are triggering a brain drain — and American scientists are panicking. Why it matters: U.S. researchers' fears are coming true. America's science pipeline is drying up, and countries like China are seizing the opportunity to surge ahead. 'This is such a race for being the science powerhouse that you never fully recover,' says Marcia McNutt, president of the National Academy of Sciences. 'You might accelerate back up to 60, but you can't make up for those years when you were at a standstill while the competition was racing ahead.' Driving the news: The National Science Foundation, which funds much of America's fundamental science research, is already doling out grants at its slowest pace in 35 years, The New York Times reports. More cuts to science could come with the "big, beautiful bill." Universities are also watching with bated breath as the administration tries to limit the number of foreign students studying in the U.S.. Harvard is pushing back, but could face a total ban on recruiting internationally. The Trump administration says it will " aggressively revoke" visas for Chinese students studying in "critical fields." By the numbers: While American universities are rescinding offers to incoming PhD students, other countries are recruiting heavily from U.S. labs. The journal Nature analyzed data from its jobs platform to track where scientists are looking for work. In the first few months of the Trump administration, there were jumps in the the number of U.S. applicants looking for jobs in Canada (+41%), Europe (+32%), China (+20%) and other Asian countries (+39%), compared to the same period in 2024. U.S. jobs saw fewer applications from candidates in Canada (–13%) and Europe (–41%). Case in point: France's Aix-Marseille University, which made headlines for earmarking millions of dollars for U.S. scientists, closed its application window after receiving a flood of apps. After American Nobel laureate Ardem Patapoutian's federal grant was frozen, he got an email from China offering 20 years of funding if he relocates his lab, The New York Times' Kate Zernike writes. He declined. 'This is a once-in-a-century brain gain opportunity,' the Australian Strategic Policy Institute wrote in a brief. The other side: The White House argues that its changes to the system will usher in a golden age of science and rebuild public trust. President Trump has also suggested that spots freed up by rejecting international students could be filled by American applicants. But professors say this isn't entirely realistic. "In hard sciences, in astronomy and physics and computer science, for example, there's no way you would fill that hole with local applicants of comparable quality," says Chris Impey, an astronomer at the University of Arizona. What to watch: 'The optimistic part of all of us thinks science is strong enough to outlast one administration, and for a while I thought that, but the hit to young people is at the center of the whole enterprise,' Impey says. 'It's like pulling the rug out from under the whole thing." It's not just brain drain of existing talent, he says. Students who are in high school and college now and thinking about a career in research might reconsider. "There's plenty of things smart kids can do. They don't have to go into science." At the same time, McNutt says she tells students: "If you went into graduate school in the fall of this year, by the time you get your PhD, this madness may be over. You come out with your new PhD ready to fill the gap."
Yahoo
a day ago
- Yahoo
Elon Musk trades threats with Trump: What it could mean for SpaceX launches in Florida
When President Donald Trump took office in January, he began offering plenty of signs that his goals for U.S. spaceflight aligned closely with those of billionaire tech mogul Elon Musk. Now those goals, which included making reaching Mars during Trump's second term a top priority, appear to be up in the air amid an increasingly volatile fallout between two of the world's most powerful men. As insults have turned to threats, Trump has suggested he'd hit Musk where it could hurt most: His wallet. Musk's SpaceX has spent years positioning itself at the center of American civil and military spaceflight – a profitable relationship that has made the company's CEO incredibly wealthy. In response, Musk has floated – and then retracted – the idea of decommissioning a SpaceX vehicle critical to NASA's spaceflight program. The vast majority of SpaceX's missions with NASA and the government launch from Cape Canaveral, either from the space agency's Kennedy Space Center or the Cape Canaveral Space Force Station. Serious threats, or empty words? That remains to be seen as Musk and Trump reportedly consider a détente. In the meantime, here's what to know about what's at stake if the U.S. government's relationship with SpaceX were to crumble: U.S. spaceflight: Trump looks to axe many NASA space missions that launched from Florida The feud between Trump and his former top advisory escalated in a dramatic fashion when the president threatened to cut off the taxpayer dollars that have fueled the growth of SpaceX, of which Musk is the CEO. "The easiest way to save money in our Budget, Billions and Billions of Dollars, is to terminate Elon's Governmental Subsidies and Contracts," Trump said in a post on his social media platform. "I was always surprised that Biden didn't do it!" In all, Musk and his businesses have received at least $38 billion in government contracts, loans, subsidies and tax credits, a Washington Post analysis found. How the potential fallout between two of the world's most powerful men could affect U.S. spaceflight ambitions remains to be seen. NASA Press Secretary Bethany Stevens said in a post on social media site X that 'NASA will continue to execute upon the President's vision for the future of space.' 'We will continue to work with our industry partners to ensure the President's objectives in space are met,' Stevens wrote. Elon Musk, the world's richest man, founded Space Exploration Technologies Corp., more widely known as SpaceX, in 2002. The commercial spaceflight company is headquartered at Starbase in South Texas. The site, which is where SpaceX has been conducting routine flight tests of its 400-foot megarocket known as Starship, was recently voted by residents to become its own city. SpaceX benefits from billions of dollars in contracts from NASA and the Department of Defense, which use many of the company's spacecraft to help launch government missions. SpaceX also conducts many of its own rocket launches, most using the Falcon 9 rocket. That includes a regular cadence of deliveries of Starlink internet satellites into orbit from both California and Florida, and occasional privately-funded commercial crewed missions on the Dragon. SpaceX is also planning to bring its Starship operations to Florida by the end of 2025. The most recent of SpaceX's private human spaceflights, a mission known as Fram2, took place in April. SpaceX was also famously involved in funding and operating the headline-grabbing Polaris Dawn crewed commercial mission in September 2024. SpaceX provides launch services to the Pentagon, including the launch of classified satellites and other payloads. CEO Gwynne Shotwell has said the company has about $22 billion in government contracts, according to Reuters. The vast majority of that, about $15 billion, is derived from NASA. SpaceX's famous two-stage Falcon 9 rocket ‒ one of the world's most active ‒ is routinely the rocket of choice to get many NASA missions off the ground. For instance, the rocket is due in the days ahead to help propel a four-person crew of private astronauts to the International Space Station for a venture with NASA known as Axiom Mission 4. NASA also has plans to use SpaceX's Starship in its Artemis lunar missions to ferry astronauts aboard the Orion capsule from orbit to the moon's surface. The rocket, which is in development, has yet to reach orbit in any of its nine flight tests beginning in April 2023. SpaceX's Dragon capsule is also a famous vehicle that is widely used for a variety of spaceflights. The capsule, which sits atop the Falcon 9 for launches to orbit, is capable of transporting both NASA astronauts and cargo to the space station. Under NASA's commercial crew program, the U.S. space agency has been paying SpaceX for years to conduct routine spaceflights to the International Space Station using the company's own launch vehicles. The first of SpaceX's Crew missions ferrying astronauts to the orbital outpost on the Dragon began in 2020, with the tenth and most recent contingent reaching the station in March for about a six-month stay. Standing nearly 27 feet tall and about 13 feet wide, Dragon capsules can carry up to seven astronauts into orbit, though most of SpaceX's Crew missions feature a crew of four. The Dragon spacecraft also was the vehicle NASA selected to bring home the two NASA astronauts who rode the doomed Boeing Starliner capsule to the space station in June 2024. Certifying the Starliner capsule for operation would give NASA a second vehicle in addition to Dragon for regular spaceflights to orbit. Because Boeing is still developing its Starliner capsule, Dragon is the only U.S. vehicle capable of carrying astronauts to and from the space station. It's also one of four vehicles contracted to transport cargo and other supplies to the orbital laboratory. For that reason, Musk's threat Thursday, June 5 to decommission the Dragon "immediately" would be a severe blow to NASA if he were to follow through on it. Musk, though, appears to already be backing off on the suggestion, which he made in response to Trump's own threats. In response to a user who advised Musk to "Cool off and take a step back for a couple days," Musk replied: 'Good advice. Ok, we won't decommission Dragon.' Seven astronauts are aboard the International Space Station, including three Americans. Four of the astronauts rode a SpaceX Dragon to the station for a mission known as Crew-10, while the remaining three launched on a Russian Soyuz spacecraft. Contributing: Joey Garrison, Josh Meyer, USA TODAY; Reuters Eric Lagatta is the Space Connect reporter for the USA TODAY Network. Reach him at elagatta@ This article originally appeared on Florida Today: SpaceX at center of Trump, Musk feud: What it could mean for Florida
